Related Experiment Video
Updated: Aug 13, 2025
Engineering Antiviral Agents via Surface Plasmon Resonance
Published on: June 14, 2022
Design and Characterization of Mutated Variants of the Oncotoxic Parvoviral Protein NS1
Patrick Hauswirth1, Philipp Graber1, Katarzyna Buczak2
1Division of Pharmaceutical Technology, Department of Pharmaceutical Sciences, University of Basel, 4056 Basel, Switzerland.
Abstract:
Oncotoxic proteins such as the non-structural protein 1 (NS1), a constituent of the rodent parvovirus H1 (H1-PV), offer a novel approach for treatment of tumors that are refractory to other treatments. In the present study, mutated NS1 variants were designed and tested with respect to their oncotoxic potential in human hepatocellular carcinoma cell lines. We introduced single point mutations of previously described important residues of the wild-type NS1 protein and a deletion of 114 base pairs localized within the N-terminal domain of NS1. Cell-viability screening with HepG2 and Hep3B hepatocarcinoma cells transfected with the constructed NS1-mutants led to identification of the single-amino acid NS1-mutant NS1-T585E, which led to a 30% decrease in cell viability as compared to NS1 wildtype. Using proteomics analysis, we could identify new interaction partners and signaling pathways of NS1. We could thus identify new oncotoxic NS1 variants and gain insight into the modes of action of NS1, which is exclusively toxic to human cancer cells. Our in-vitro studies provide mechanistic explanations for the observed oncolytic effects. Expression of NS1 variants had no effect on cell viability in NS1 unresponsive control HepG2 cells or primary mouse hepatocytes. The availability of new NS1 variants in combination with a better understanding of their modes of action offers new possibilities for the design of innovative cancer treatment strategies.
Insights
Researchers engineered mutated non-structural protein 1 (NS1) variants from H1-parvovirus, identifying NS1-T585E as a potent oncotoxic agent against liver cancer cells. This discovery enhances understanding of NS1
Area of Science:
- Oncology
- Virology
- Molecular Biology
Background:
- Non-structural protein 1 (NS1) from H1-parvovirus exhibits oncotoxic properties.
- Hepatocellular carcinoma (HCC) remains a significant challenge, often refractory to conventional therapies.
Purpose of the Study:
- To design and evaluate novel NS1 variants for enhanced oncotoxicity against human HCC cell lines.
- To elucidate the mechanisms of action and identify new interaction partners of NS1.
Main Methods:
- Introduction of single point mutations and N-terminal domain deletions into the wild-type NS1 gene.
- Cell viability assays using HepG2 and Hep3B HCC cell lines transfected with NS1 mutants.
- Proteomics analysis to identify NS1 interaction partners and signaling pathways.
Main Results:
- The NS1-T585E single-amino acid mutant demonstrated a 30% decrease in HCC cell viability compared to wild-type NS1.
- Proteomics identified novel interaction partners and signaling pathways modulated by NS1.
- NS1 variants showed specific toxicity to cancer cells, with no impact on control cells or primary hepatocytes.
Conclusions:
- NS1-T585E represents a promising new oncotoxic variant for potential HCC treatment.
- Understanding NS1's mechanism of action provides a foundation for developing innovative cancer therapies.
- Targeted NS1 variants offer a novel strategy for treating refractory tumors.
